CLINICAL TRIALS PROFILE FOR TESTOSTERONE CYPIONATE

All Clinical Trials for TESTOSTERONE CYPIONATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00853502 ↗	The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa	Withdrawn	Massachusetts General Hospital	Phase 2	2008-12-01	Decreased bone strength is a common and serious medical problem present in many people with anorexia nervosa. Men with anorexia nervosa have lower levels of gonadal steroids such as testosterone. Low testosterone levels have been shown to result in low bone density. We are investigating whether bone mineral density and bone microarchitecture are abnormal in males with anorexia nervosa and whether supplementation with testosterone would improve both bone mineral density and bone microarchitecture.
NCT00965341 ↗	Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients	Completed	M.D. Anderson Cancer Center	Phase 3	2009-09-01	The goal of this clinical research study is to learn if and how testosterone replacement therapy may affect fatigue in males with advanced cancer and low testosterone levels.
NCT01084759 ↗	A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer	Completed	Sidney Kimmel Comprehensive Cancer Center	N/A	2010-03-01	The objective of the study is to determine if men with evidence of progressive prostate cancer while on chronic androgen ablation of ≥ 1 year duration will exhibit a clinical response following administration of parenteral testosterone and oral etoposide. Treatment Plan: Eligible patients will continue on androgen ablative therapy with luteinizing hormone-releasing hormone (LHRH) agonist (i.e. Zoladex or Lupron) if not surgically castrated. Patients will receive intramuscular injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This dose was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. > 3-5 times normal level) with eugonadal levels achieved at the end of two weeks. Beginning the day of the testosterone injection, patients will also receive oral etoposide 100 mg/day in divided doses (50 mg q 12h) x 14 days out of 28 days per cycle. After 3 months on therapy, patients will have repeat prostate specific antigen (PSA) and bone/computed tomography (CT) scans to establish the effect of combined testosterone and etoposide treatment on these parameters (i.e. "testosterone effect baseline"). Patients with sustained elevations in PSA ≥ 50% above pre-testosterone treatment PSA levels after the initial three months of testosterone and etoposide therapy will not receive continued therapy and will come off study. Patients with PSA levels less than the peak serum PSA level seen over the three month period (PSA decline) or patients with PSA ≤ 50% of pretreatment baseline will receive a second 3 month course of monthly testosterone and etoposide therapy until evidence of disease progression. Disease progression is defined as a PSA increase above the PSA level obtained after 3 months on testosterone treatment over two successive measurements 2 weeks apart or evidence of new lesions or progression on bone/CT scans compared to baseline studies. Patients who respond to initial treatment with testosterone and etoposide and then show signs of progression will have the option of retreatment with testosterone alone after a period of 3 months or greater off of the original therapy.
NCT01084759 ↗	A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	N/A	2010-03-01	The objective of the study is to determine if men with evidence of progressive prostate cancer while on chronic androgen ablation of ≥ 1 year duration will exhibit a clinical response following administration of parenteral testosterone and oral etoposide. Treatment Plan: Eligible patients will continue on androgen ablative therapy with luteinizing hormone-releasing hormone (LHRH) agonist (i.e. Zoladex or Lupron) if not surgically castrated. Patients will receive intramuscular injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This dose was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. > 3-5 times normal level) with eugonadal levels achieved at the end of two weeks. Beginning the day of the testosterone injection, patients will also receive oral etoposide 100 mg/day in divided doses (50 mg q 12h) x 14 days out of 28 days per cycle. After 3 months on therapy, patients will have repeat prostate specific antigen (PSA) and bone/computed tomography (CT) scans to establish the effect of combined testosterone and etoposide treatment on these parameters (i.e. "testosterone effect baseline"). Patients with sustained elevations in PSA ≥ 50% above pre-testosterone treatment PSA levels after the initial three months of testosterone and etoposide therapy will not receive continued therapy and will come off study. Patients with PSA levels less than the peak serum PSA level seen over the three month period (PSA decline) or patients with PSA ≤ 50% of pretreatment baseline will receive a second 3 month course of monthly testosterone and etoposide therapy until evidence of disease progression. Disease progression is defined as a PSA increase above the PSA level obtained after 3 months on testosterone treatment over two successive measurements 2 weeks apart or evidence of new lesions or progression on bone/CT scans compared to baseline studies. Patients who respond to initial treatment with testosterone and etoposide and then show signs of progression will have the option of retreatment with testosterone alone after a period of 3 months or greater off of the original therapy.
NCT01378299 ↗	CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy	Completed	Baylor College of Medicine	Phase 1	2011-10-01	Testosterone (T) replacement prevents bone loss and relieves symptoms associated with androgen deficiency in male patients with hypogonadism, but at the expense of an increase in prostate-related adverse events and in the hematocrit values above the normal which may lead to bad circulatory outcomes. Most of the effects of T on the male skeleton are mediated by its conversion to estradiol (E2) by the enzyme aromatase. Genetic variations in the aromatase (CYP19A1) gene result in enzymes with variable activity and variable levels of E2 and T. This project is designed to determine if genetic variations in the CYP19A1 gene will result in differences in the skeletal response and incidence of side effects from T treatment in patients with low T. A large number of male Veterans are on T. Results from this project will help identify patients who would benefit from the therapy from those at risk for side effects, and would definitely have an impact in the future care of these patients and male patients in general once genetic profiling becomes part of the standard of care.
NCT01378299 ↗	CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy	Completed	VA Office of Research and Development	Phase 1	2011-10-01	Testosterone (T) replacement prevents bone loss and relieves symptoms associated with androgen deficiency in male patients with hypogonadism, but at the expense of an increase in prostate-related adverse events and in the hematocrit values above the normal which may lead to bad circulatory outcomes. Most of the effects of T on the male skeleton are mediated by its conversion to estradiol (E2) by the enzyme aromatase. Genetic variations in the aromatase (CYP19A1) gene result in enzymes with variable activity and variable levels of E2 and T. This project is designed to determine if genetic variations in the CYP19A1 gene will result in differences in the skeletal response and incidence of side effects from T treatment in patients with low T. A large number of male Veterans are on T. Results from this project will help identify patients who would benefit from the therapy from those at risk for side effects, and would definitely have an impact in the future care of these patients and male patients in general once genetic profiling becomes part of the standard of care.
NCT01750398 ↗	Bipolar Androgen-based Therapy for Prostate Cancer (BAT)	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	2013-01-01	The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the effect of alternating therapy on quality of life and metabolic changes associated with androgen-deprivation therapy.

Clinical Trial Conditions for TESTOSTERONE CYPIONATE

Condition Name

Condition Name for TESTOSTERONE CYPIONATE
Intervention	Trials
Prostate Cancer	9
Hypogonadism, Male	6
Metastatic Castration-resistant Prostate Cancer	4
Castration-Resistant Prostate Carcinoma	3

Condition MeSH

Condition MeSH for TESTOSTERONE CYPIONATE
Intervention	Trials
Prostatic Neoplasms	19
Hypogonadism	9
Eunuchism	6
Fatigue	2

Clinical Trial Locations for TESTOSTERONE CYPIONATE

Trials by Country

Trials by Country for TESTOSTERONE CYPIONATE
Location	Trials
United States	52
Brazil	8
Canada	1
Spain	1

Trials by US State

Trials by US State for TESTOSTERONE CYPIONATE
Location	Trials
Maryland	12
Massachusetts	5
Texas	4
Washington	4
Florida	3

Clinical Trial Progress for TESTOSTERONE CYPIONATE

Clinical Trial Phase

Clinical Trial Phase for TESTOSTERONE CYPIONATE
Clinical Trial Phase	Trials
PHASE4	5
PHASE2	2
PHASE1	1

Clinical Trial Status

Clinical Trial Status for TESTOSTERONE CYPIONATE
Clinical Trial Phase	Trials
Recruiting	12
Completed	8
Not yet recruiting	7

Clinical Trial Sponsors for TESTOSTERONE CYPIONATE

Sponsor Name

Sponsor Name for TESTOSTERONE CYPIONATE
Sponsor	Trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	12
Sidney Kimmel Comprehensive Cancer Center	5
National Cancer Institute (NCI)	4

Sponsor Type

Sponsor Type for TESTOSTERONE CYPIONATE
Sponsor	Trials
Other	47
Industry	9
NIH	5

Testosterone Cypionate: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

This report analyzes the current clinical trial landscape, market performance, and future projections for Testosterone Cypionate, a widely used androgen replacement therapy. The analysis focuses on key regulatory developments, competitive forces, and therapeutic applications driving market trends.

What is the Current Clinical Trial Landscape for Testosterone Cypionate?

As of the most recent data available, Testosterone Cypionate is primarily used for the treatment of hypogonadism in adult males. Clinical trial activity surrounding this established drug is limited, with a focus on post-market surveillance, comparative effectiveness studies, and investigations into novel delivery systems or specific patient sub-populations rather than primary efficacy and safety research.

Active and Recently Completed Trials

The majority of ongoing clinical trials involving Testosterone Cypionate are observational or comparative in nature. These studies aim to gather real-world evidence on long-term outcomes, adverse event profiles in diverse populations, and comparisons against other testosterone formulations.

• Observational Studies: These trials often focus on tracking patient adherence, metabolic outcomes, cardiovascular health markers, and the incidence of specific side effects in men receiving Testosterone Cypionate for various durations and dosages. Data is typically collected through patient records, surveys, and periodic clinical assessments.
• Comparative Effectiveness Trials: While fewer in number, some trials compare Testosterone Cypionate to other injectable, transdermal, or implantable testosterone therapies. These studies evaluate differences in efficacy, patient satisfaction, convenience, and cost-effectiveness. For example, a trial might assess if a new depot injection formulation of testosterone cypionate offers a superior pharmacokinetic profile compared to existing intramuscular preparations.
• Formulation and Delivery System Research: Some research explores incremental improvements to existing Testosterone Cypionate formulations or novel delivery mechanisms to enhance patient convenience and plasma testosterone stability. This can include investigating modified-release injections or exploring excipients that prolong drug release.

The absence of large-scale, Phase III trials for new indications or primary efficacy endpoints suggests that the drug's therapeutic role is well-defined and its market positioning is mature. Regulatory bodies like the U.S. Food and Drug Administration (FDA) have approved Testosterone Cypionate for its established uses, and significant changes in its core indications are unlikely without substantial new evidence.

Regulatory Status and Post-Market Surveillance

Testosterone Cypionate is a U.S. Drug Enforcement Administration (DEA) Schedule III controlled substance due to its potential for abuse and dependence. This classification necessitates stringent prescribing and dispensing regulations. Post-market surveillance by regulatory agencies continues to monitor for any emerging safety signals. Any new safety information or adverse event trends identified through pharmacovigilance can lead to updated labeling, restricted use, or, in rare cases, market withdrawal. However, given its long history of use and established safety profile when used appropriately, significant regulatory actions are not anticipated.

What is the Market Analysis for Testosterone Cypionate?

The market for Testosterone Cypionate is characterized by its stability, driven by consistent demand for androgen replacement therapy. Its established efficacy, cost-effectiveness compared to some newer formulations, and wide physician familiarity contribute to its sustained market share.

Market Size and Growth Drivers

The global testosterone replacement therapy market, which includes Testosterone Cypionate, was valued at approximately $2.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 4.5% to reach an estimated $3.0 billion by 2028 [1]. Testosterone Cypionate holds a significant segment of this market due to its established presence and affordability.

Key market drivers include:

• Increasing Prevalence of Hypogonadism: A growing aging male population and increased awareness of hypogonadism contribute to rising diagnosis rates. Conditions such as obesity, diabetes, and chronic illnesses are also linked to lower testosterone levels, further expanding the patient pool.
• Diagnostic Advancements: Improved diagnostic tools and physician awareness facilitate earlier and more accurate identification of hypogonadal men.
• Physician and Patient Familiarity: Testosterone Cypionate has been a cornerstone of testosterone therapy for decades. Physicians are well-versed in its administration, dosing, and potential side effects, fostering prescribing confidence. Patients also have a high level of familiarity and acceptance.
• Cost-Effectiveness: Compared to newer, more complex formulations (e.g., transdermal patches, gels, long-acting injectables), Testosterone Cypionate injections often represent a more economical treatment option for patients and healthcare systems.

Competitive Landscape

The market is competitive, with several pharmaceutical companies manufacturing and distributing Testosterone Cypionate. The primary competitive factors are price, product availability, and physician relationships.

• Key Manufacturers: Major players in the Testosterone Cypionate market include AbbVie (AndroGel, though this is a gel formulation, it represents a major TRT player), Endo Pharmaceuticals, and various generic manufacturers. The market is also supplied by compounding pharmacies, which can offer customized formulations but are subject to different regulatory oversight.
• Generic Competition: As a molecule with expired primary patents, Testosterone Cypionate is widely available as a generic product. This intensifies price competition among manufacturers and suppliers.
• Alternative Therapies: Testosterone Cypionate competes directly with other testosterone formulations, including:
  • Other Injectables: Testosterone Enanthate, Testosterone Undecanoate (longer-acting).
  • Transdermal Gels and Patches: Offer daily application but can cause skin irritation and transference risk.
  • Testosterone Pellets: Long-acting subcutaneous implants providing sustained release for months.
  • Oral Testosterone: Limited options due to liver toxicity concerns, though newer formulations are emerging.

The choice between these therapies often depends on patient preference for administration frequency and method, cost, and physician recommendation based on individual patient needs and pharmacokinetic profiles.

Pricing Trends and Market Access

Pricing for Testosterone Cypionate has remained relatively stable, influenced by generic competition. While branded products exist, generic versions dominate the market, driving down per-unit costs. Market access is generally broad, as it is a widely prescribed medication covered by most insurance plans for approved indications. However, the DEA Schedule III classification adds administrative requirements for prescribers and pharmacies.

What are the Market Projections for Testosterone Cypionate?

The market for Testosterone Cypionate is projected to maintain steady growth, driven by the persistent underlying demand for testosterone replacement therapy. While significant disruption from novel therapeutic modalities is unlikely to displace injectable testosterone entirely, gradual shifts in patient preference and the introduction of more convenient or physician-preferred alternatives could influence market share over the long term.

Future Market Growth

The projected CAGR of approximately 4.5% for the broader TRT market suggests a similar, if not slightly more conservative, growth trajectory for Testosterone Cypionate specifically. The sustained demand from the aging male population and increasing diagnosis rates will continue to underpin this growth.

• Continued Demand: The fundamental reasons for prescribing Testosterone Cypionate – treating hypogonadism – will not disappear. As the global population ages, the incidence of conditions associated with lower testosterone levels is expected to increase.
• Role in Managed Care: Its cost-effectiveness makes it a favored choice within managed care formularies, particularly for long-term treatment where cost per year is a significant consideration. This will help it retain a substantial market share against more expensive alternatives.
• Generics Dominance: The market will continue to be characterized by generic competition, with pricing remaining a key differentiator. Manufacturers focusing on efficient production and supply chain management will likely maintain a competitive edge.

Emerging Trends and Potential Disruptors

While the market is mature, several trends could influence its future:

• Advancements in Delivery Systems: The development of longer-acting injectable testosterone formulations or more convenient transdermal systems could draw some patients away from traditional Testosterone Cypionate injections, especially those seeking less frequent administration. For example, testosterone undecanoate injections, with their longer dosing intervals, are gaining traction.
• Personalized Medicine Approaches: As understanding of individual responses to testosterone therapy evolves, there may be a push towards more personalized treatment regimens, potentially favoring formulations with more predictable pharmacokinetics or patient-specific dosing adjustments.
• Telemedicine and Direct-to-Consumer Models: The rise of telemedicine and direct-to-consumer health platforms could alter how TRT is accessed and managed. While Testosterone Cypionate can be prescribed in these settings, the physical administration of injections requires a healthcare provider or trained individual, potentially favoring non-injectable options for some patients.
• Increased Scrutiny on Long-Term Cardiovascular and Oncological Outcomes: Ongoing research into the long-term cardiovascular and oncological risks associated with TRT could influence prescribing patterns and patient selection, although current evidence does not definitively link Testosterone Cypionate to increased risks when used appropriately.

Geographic Market Considerations

North America and Europe are currently the largest markets for Testosterone Cypionate, driven by high awareness, established healthcare infrastructure, and advanced diagnostic capabilities. Emerging economies in Asia-Pacific and Latin America are expected to witness higher growth rates due to increasing healthcare expenditure, rising diagnosis rates, and a growing middle class with better access to medical treatments.

Table 1: Global Testosterone Replacement Therapy Market Segmentation (Estimated 2022)

Segment	Market Share (%)	Key Drivers
Injectable	35-40%	Cost-effectiveness, physician familiarity, established efficacy
Transdermal	30-35%	Convenience, stable hormone levels, patient preference
Oral	5-10%	Emerging formulations, patient aversion to injections/transdermals
Pellets/Implants	10-15%	Long-acting, convenience, sustained release
Other (e.g., Nasal)	<5%	Niche applications, emerging technologies

Note: Figures are estimates and may vary based on specific market research reports and segmentation methodologies. Testosterone Cypionate primarily falls within the "Injectable" segment.

Strategic Outlook for Stakeholders

• Manufacturers: Focus on cost-efficient production, robust supply chain management, and maintaining strong relationships with distributors and healthcare providers. Exploring incremental formulation improvements or combination therapies could offer differentiation.
• Healthcare Providers: Continue to leverage established prescribing guidelines for Testosterone Cypionate. Stay abreast of comparative data for alternative formulations to optimize patient care and tailor treatment to individual needs.
• Payers: Continue to recognize Testosterone Cypionate as a cost-effective option for hypogonadism management, balancing cost with therapeutic outcomes. Monitor real-world data on long-term safety and efficacy.

Key Takeaways

Testosterone Cypionate remains a cornerstone of androgen replacement therapy, characterized by its stability and cost-effectiveness. The drug's clinical trial activity is minimal, reflecting its mature market status, with ongoing research primarily focused on post-market surveillance and comparative effectiveness. The market is driven by the increasing prevalence of hypogonadism, diagnostic advancements, and physician/patient familiarity. Despite competition from newer formulations, Testosterone Cypionate is projected to maintain steady market growth, underpinned by its economic advantages and broad accessibility within healthcare systems. Future market dynamics will be influenced by evolving delivery systems, personalized medicine approaches, and shifts in healthcare access models.

Frequently Asked Questions

1. What are the primary indications for Testosterone Cypionate? Testosterone Cypionate is primarily indicated for testosterone replacement therapy in adult males diagnosed with hypogonadism due to a deficiency or absence of endogenous testosterone.

2. How does Testosterone Cypionate compare in cost to other testosterone formulations? Testosterone Cypionate, particularly in its generic forms, is generally more cost-effective on a per-dose or per-treatment-cycle basis compared to many transdermal gels, patches, pellets, and longer-acting injectable formulations.

3. What is the typical administration frequency for Testosterone Cypionate injections? The typical administration frequency for intramuscular Testosterone Cypionate is every one to two weeks, although dosing schedules can vary based on individual patient response, physician preference, and specific formulation pharmacokinetics.

4. Are there any significant new clinical trials exploring Testosterone Cypionate for novel indications? As of current data, there are no large-scale, pivotal clinical trials investigating Testosterone Cypionate for entirely new indications. Research is predominantly focused on optimizing its use within its approved therapeutic areas or comparing its outcomes to alternative treatments.

5. What regulatory considerations are associated with prescribing Testosterone Cypionate? Testosterone Cypionate is a DEA Schedule III controlled substance in the United States, requiring specific prescription protocols, refill limitations, and careful record-keeping by both prescribers and pharmacies to prevent diversion and abuse.

---

Citations

[1] Grand View Research. (2023). Testosterone Replacement Therapy Market Size, Share & Trends Analysis Report By Type (Injectable, Transdermal, Oral, Pellets), By Application (Hypogonadism, Erectile Dysfunction, Contraception), By End-use, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/testosterone-replacement-therapy-market